Metraipolis › archive › dc_8da01403e882

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma — Europe PMC PMID:42133639

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42133639
DOI
10.1371/journal.pone.0349044
License (as archived)
solo-consultazione
Archived
2026-10-07T21:46:04.033Z
SHA-256 of the archived text
33084fc187dc69d73c5214bbe1873ac5db0c60f4f6dbaaa01e1a9be825c55060
Stable URL of this page
https://metraipolis.com/documento/dc_8da01403e882

How to cite

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma — Europe PMC PMID:42133639 — Europe PMC (en), https://europepmc.org/article/MED/42133639 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8da01403e882 (Metraipolis archive dc_8da01403e882, sha256 33084fc187dc69d73c5214bbe1873ac5db0c60f4f6dbaaa01e1a9be825c55060)
BibTeX
@misc{dc8da01403e882,
  title = {Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma — Europe PMC PMID:42133639},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42133639},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8da01403e882; sha256 33084fc187dc69d73c5214bbe1873ac5db0c60f4f6dbaaa01e1a9be825c55060},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42133639. Agents can read the archived copy with the MCP tool read_document.